drugset
drugset / Trial / NCT04128007

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

NCT04128007 ↗

Phase 2 Completed 304 enrolled Arcutis Biotherapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis

Timeline

Start
2020-01-13
Primary completion
2020-09-23
Completion
2020-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Roflumilast Small molecule 0.3 % —

Indications

psoriasis